Clinical Trials Browser

Phase 1 × Irinotecan × CNS × Clear all

NCT06995872 2026-02-17

Phase I Trial of rhIL-15 Plus Dinutuximab Plus Irinotecan/Temozolomide for Children and Young Adults With Relapsed/Refractory Neuroblastoma

Phase 1 Recruiting

Neuroblastoma

NCT05421897 2026-01-29

RAPID

Phase 1 Active not recruiting

Neoplasms, Neuroblastoma

NCT05400603 2025-12-26

Aflac-NBL-2002

Phase 1 Recruiting

Neuroblastoma, Osteosarcoma

NCT02192359 2025-11-14

Carboxylesterase-Expressing Allogeneic Neural Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas

Phase 1 Active not recruiting

18 enrolled 16 charts

Astrocytoma, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

NCT04239092 2025-07-17

9-ING-41 in Pediatric Patients With Refractory Malignancies.

Phase 1 Terminated

Diffuse Intrinsic Pontine Glioma, Meningioma, Neoplasms, Neuroblastoma

NCT07027748 2025-07-14

Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma

Phase 1 Recruiting

Neuroblastoma

NCT02975882 2025-01-14

Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors

Phase 1 Completed

33 enrolled 15 charts

Central Nervous System Neoplasms

NCT04525014 2024-10-31

PIRATE

Phase 1 Terminated

Brain Neoplasms, Neoplasms, Spinal Cord Neoplasms, Central Nervous System Neoplasms

NCT02085148 2024-04-22

A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy

Phase 1 Completed

CNSGastrointestinalGenitourinarySarcoma

Neoplasms, Wilms Tumor, Neuroblastoma, Rhabdomyosarcoma, Sarcoma, Ewing, Hepatoblastoma

NCT00876993 2023-07-03

Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors

Phase 1 Completed

26 enrolled 16 charts

Central Nervous System Neoplasms

NCT01528046 2023-01-13

Metformin in Children With Relapsed or Refractory Solid Tumors

Phase 1 Completed

Brain Neoplasms, Neoplasms, Recurrence

NCT00671801 2018-11-13

Irinotecan Plus Lenalidomide in Adult Patients With Recurrent Glioblastoma Multiforme: Phase I

Phase 1 Terminated

Astrocytoma, Glioblastoma, Glioma, Oligodendroglioma, Gliosarcoma

NCT00960063 2018-08-27

A Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Pediatric Participants With Advanced Solid Tumors (P05883, MK-7454-006)

Phase 1 Terminated

4 enrolled 8 charts

CNSGenitourinarySarcoma

Bone Neoplasms, Carcinoma, Renal Cell, Neoplasms, Neuroblastoma

NCT00644696 2017-07-06

Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma

Phase 1 Completed

Neuroblastoma

NCT00003484 2015-04-23

Radiolabeled Monoclonal Antibody Therapy After Radiation Therapy in Treating Patients With Primary Brain Tumors

Phase 1 Completed

Astrocytoma, Brain Neoplasms, Craniopharyngioma, Glioblastoma, Glioma, Medulloblastoma, Meningioma, Neuroblastoma, Oligodendroglioma, Pinealoma, Central Nervous System Neoplasms, Gliosarcoma

NCT01518413 2015-02-27

Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Solid Tumors

Phase 1 Completed

Brain Neoplasms, Neuroblastoma, Rhabdomyosarcoma, Osteosarcoma

NCT00005951 2014-08-22

Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma

Phase 1 Completed

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma, Central Nervous System Neoplasms, Gliosarcoma

NCT00611728 2014-07-21

Ph I SU011248 + Irinotecan in Treatment of Pts w MG

Phase 1 Completed

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma

NCT02055196 2014-06-02

Genetically Modified Stem Cells and Irinotecan Hydrochloride in Treating Patients With Recurrent High-Grade Gliomas

Phase 1 Withdrawn

Astrocytoma, Brain Neoplasms, Glioblastoma, Oligodendroglioma, Gliosarcoma

NCT00031681 2013-09-30

7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)

Phase 1 Completed

BreastCNSGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Anus Neoplasms, Appendiceal Neoplasms, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Esthesioneuroblastoma, Olfactory, Gastrointestinal Stromal Tumors, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT00762255 2013-07-25

A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma

Phase 1 Completed

Glioblastoma, Neurologic Manifestations

NCT00002988 2013-06-20

Irinotecan Plus Carmustine in Treating Patients With Recurrent Primary Malignant Glioma

Phase 1 Completed

Brain Neoplasms, Central Nervous System Neoplasms

NCT00612638 2013-06-19

Ph. I Temozolomide + O6-BG + Irinotecan in Treatment of Pts w Recurrent / Progressive Cerebral Anaplastic Gliomas

Phase 1 Completed

Glioblastoma, Glioma, Gliosarcoma

NCT00101270 2013-06-05

Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas

Phase 1 Completed

CNSDermatologicGastrointestinalGenitourinaryHead & NeckLymphoidSarcoma

Familial ependymoma, Astrocytoma, Burkitt Lymphoma, Colonic Neoplasms, Medulloblastoma, Melanoma, Nasopharyngeal Neoplasms, Wilms Tumor, Neuroblastoma, Recurrence, Osteosarcoma, Lymphoma, Large B-Cell, Diffuse, Neuroectodermal Tumors, Primitive, Peripheral, Optic Nerve Glioma, Dendritic Cell Sarcoma, Interdigitating

NCT00093353 2010-10-15

N2003-01: Irinotecan, Temozolomide, and Cefixime in Treating Young Patients With Recurrent or Resistant Neuroblastoma

Phase 1 Completed

Diarrhea, Neuroblastoma, Drug-Related Side Effects and Adverse Reactions

NCT00251797 2010-01-07

A Phase I Trial Using Combination Irinotecan and Thalidomide for Recurrent CNS Tumors

Phase 1 Completed

Brain Neoplasms, Neoplasms, Neurologic Manifestations, Central Nervous System Neoplasms